Page 66 - Bio Engineering Approaches to Cancer Diagnosis and Treatment

64 CHAPTER 3 Immune assay assisted cancer diagnostic

In cancer diagnostic methods, aside from the cost, accuracy, and trustworthiness,
other factors are important too, in particular the noninvasiveness of the method. The
usage of body fluids such as oral saliva, urine, and blood, is more attractive for detec-
tion of biomarkers with high sensitivity and specificity, and they are also far less
invasive for patients. Choose of urine as a body fluid with an immunoassay tech-
nique that could detect more accurate biomarkers for specific cancer could be a great
advance in cancer diagnosis at its early stage.
After introducing the role of immune assays in cancer diagnosis in this chapter,
the landmark effect of immunotherapy in cancer will be discussed in the following.

References
[1] R. Etzioni, N. Urban, S. Ramsey, M. McIntosh, S. Schwartz, B. Reid, et al. Early detec-
tion: the case for early detection, Nat. Rev. Cancer 3 (4) (2003) 243.
[2] C. Desmetz, A. Mange, B. Maudelonde, J. Solassol, Autoantibody signatures: progress
and perspectives for early cancer detection, J. Transl. Med. 15 (10) (2011) 2013–2024.
[3] S. Sharma, R. Raghav, R. O’Kennedy, S. Srivastava, Advances in ovarian cancer diag-
nosis: a journey from immunoassays to immunosensors, Enzyme Microb. Technol. 89
(2016) 15–30.
[4] H. Prasetya, B.B. Purnomo, I.K.G. Muliartha, S.R. Prawiro, Polyclonal antibody from
47 kDa protein of bladder cancer is sensitive and specific for detection of bladder cancer,
Biomark. Genom. Med. 6 (3) (2014) 116–120.
[5] H. Prasetya, B.B. Purnomo, K. Mintaroem, S.R. Prawiro, Sensitivity and specificity of
47kDa polyclonal antibody for detection of bladder cancer cells in urine of hematuria
patients, Afr. J. Urol. 24 (4) (2018) 264–269.
[6] A. Singh, S. Chaudhary, A. Agarwal, A.S. Verma, Antibodies: monoclonal and poly-
clonal, Animal Biotechnology, Academic Press, (2014) pp. 265–287.
[7] D.J. Brennan, D.P. O’connor, E. Rexhepaj, F. Ponten, W.M. Gallagher, Antibody-based
proteomics: fast-tracking molecular diagnostics in oncology, Nat. Rev. Cancer 10 (9)
(2010) 605.
[8] S.H. Tan, A. Rastogi, S. Banerjee, A. Bagga, C. Xavier, A. Mohamed, et al. Immuno-
biomarkers: structural and functional characterization of single chain fragment variable
(scFv) to ERG from a mouse monoclonal antibody, 78(13) (2018).
[9] A.M. Wu, Engineered antibodies for molecular imaging of cancer, Methods 65 (1) (2014)
139–147.
[10] G. Lee, E. Laflamme, C.H. Chien, H.H. Ting, Molecular identity of a pan cancer marker,
CA215, Cancer Biol. Ther. 7 (12) (2008) 2007–2014.
[11] G. Lee, Cancer cell-expressed immunoglobulins: CA215 as a pan cancer marker and its
diagnostic applications, Cancer Biomark 5 (3) (2009) 137–142.
[12] H. Torikai, A. Reik, P.Q. Liu, Y. Zhou, L. Zhang, S. Maiti, et al. A foundation for “uni-
versal” T-cell based immunotherapy: T-cells engineered to express a CD19-specific chi-
meric-antigen-receptor and eliminate expression of endogenous TCR, Blood 119 (24)
(2012) 5697–5705.
[13] G. Lee, M. Zhu, B. Ge, S. Potzold, Widespread expressions of immunoglobulin super-
family proteins in cancer cells, Cancer Immunol. Immunother. 61 (1) (2012) 89–99.